Three-year Phase 2 melanoma data anchors Evaxion's AI vaccine platform, but EVX-01 needs a partnership or registrational path before cash runs out in H2 2027

Bull

The monotherapy year-three data confirms durable, deepening responses independent of checkpoint inhibitor co-administration, validating EVX-01 as a standalone cancer vaccine and significantly strengthening the case for a partnership or Phase 3 collaboration in melanoma. An 86% neoantigen target hit rate and 92% two-year durability with zero relapses among responders would differentiate EVX-01 from competing approaches and attract pharma interest at a premium to current valuation. ESMO presentation catalyzes licensing discussions analogous to the MSD deal, providing non-dilutive capital to extend the runway well beyond the stated H2 2027 endpoint.

Bear

The trial enrolled only 16 patients, making statistical interpretation fragile and limiting the persuasiveness of the data to regulators and large pharma partners who will require substantially larger controlled trials before committing to Phase 3 or licensing. Competing approved therapies in post-anti-PD-1 advanced melanoma, including Iovance Biotherapeutics' lifileucel TIL therapy and Replimune's RP1 oncolytic virus, have larger datasets and existing commercial infrastructure, reducing urgency for partners to license an early-stage vaccine. Cash burn of approximately $3.6M per quarter against an $18.4M cash position as of March 2026 creates funding pressure that could force dilutive equity issuance before a partnership catalyst materializes.